Globus Medical, Inc. $GMED Stock Position Cut by Sterling Investment Advisors Ltd.

Sterling Investment Advisors Ltd. cut its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 8.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 144,023 shares of the medical device company’s stock after selling 13,000 shares during the quarter. Globus Medical makes up approximately 2.2% of Sterling Investment Advisors Ltd.’s holdings, making the stock its 9th largest holding. Sterling Investment Advisors Ltd.’s holdings in Globus Medical were worth $12,575,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Summitry LLC increased its holdings in Globus Medical by 18.6% during the 4th quarter. Summitry LLC now owns 7,994 shares of the medical device company’s stock worth $698,000 after purchasing an additional 1,255 shares during the last quarter. Clearstead Advisors LLC increased its holdings in Globus Medical by 123.6% during the 4th quarter. Clearstead Advisors LLC now owns 738 shares of the medical device company’s stock worth $64,000 after purchasing an additional 408 shares during the last quarter. New Age Alpha Advisors LLC increased its holdings in Globus Medical by 3.8% during the 4th quarter. New Age Alpha Advisors LLC now owns 26,659 shares of the medical device company’s stock worth $2,328,000 after purchasing an additional 977 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Globus Medical by 517.8% during the 4th quarter. Hantz Financial Services Inc. now owns 2,774 shares of the medical device company’s stock worth $242,000 after purchasing an additional 2,325 shares during the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in Globus Medical during the 4th quarter worth approximately $1,330,000. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total transaction of $1,890,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 18.38% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Truist Financial set a $115.00 price objective on Globus Medical in a report on Wednesday, February 25th. TD Cowen upgraded Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Barclays lifted their target price on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Needham & Company LLC lifted their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical presently has a consensus rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Trading Up 0.0%

Shares of GMED opened at $84.84 on Tuesday. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40. The firm has a market cap of $11.52 billion, a price-to-earnings ratio of 19.73, a PEG ratio of 1.75 and a beta of 1.00. The stock has a 50 day moving average of $87.27 and a 200-day moving average of $88.15.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same quarter in the previous year, the firm posted $0.68 EPS. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.